Step by Step

INTRODUCTION

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.25

Target Audience:

This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards.

Educational Objectives:

Upon completion of this activity, participants should be able to: 

  • Discuss what vascular anomalies encompass
  • Discuss common inpatient presentations and management with patients who have infantile hemangiomas.
  • Discuss treatment of infantile hemangioma and the common side effects of the treatment.

 

There is no educational content to this course. This course is designed to only administer the post-test and collect CME evaluations for the podcast associated with this training.


Suggested Additional Reading:

    1. Hoeger P.H, Colmenero I. Vascular tumors in infants. Part I: benign vascular tumors other than infantile hemangioma. British Journal of Dermatology. 2014. 171. Pp 466-473

    2. Colmenero I & Hoeger P.H. Vascular tumors in infants. Part II: vascular tumors of intermediate dignity and malignant tumors. British Journal of Dermatology. 2014. 171 pp 474-484
    3. Liang M, Frieden I. Infantile and Congenital Hemangiomas. Seminars in Pediatric Surgery 23 (2014). 162-167
    4. Vanderbuilt Evidence Based Practice Center. AHRQ – Diagnosis and Management of Infantile Hemangioma. AHRQ Publication No. 16-EHC002-EF January 2016
    5. Chang L et al. Growth Characteristics of Infantile Hemangiomas: Implications for Management. Pediatrics 2008;122:360-367
    6. Smith CJ, Friedlander SF, Guma M, Kavanaugh A, Chambers CD. Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Res. 2017 Apr 12
    7. Chinnadurai S et al. Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. PEDIATRICS. Volume 137 , number 2 , February 2016.
    8. Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C. The Role of Topical Timolol in the Treatment of Infantile Hemangiomas: A Systematic Review and Meta-analysis.Acta Derm Venereol. 2017 Apr 19.
    9. Christison-Lagay ER et al. Hepatic Hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surgery. 2007; 42:62-68
    10. Marsciani A et al. Massive response of severe infantile hepatic hemangioma to propranolol. Pediatr Blood Cancer 2010;54:176
    11. Horii et al. Prospective Study of the Frequency of Hepatic Hemangiomas in Infants with Multiple Cutaneous Infantile Hemangiomas. Pediatric Dermatology, 2011. Vol 25. No 3. 215-253.
    12. Drolet et al. Gastrointestinal Bleeding in Infantile Hemangioma: A Complication if Segmental, Rather than Multifocal, Infantile Hemagioma. J Pediatr 2012;160:1021-6
    13. Metry D et al. Consensus Statement on Diagnostic Criteria for PHACE Syndrome. Pediatrics. Vol 124, No 5. Nov 2009.
    14. Iacobas I et al. LUMBAR: Association between Cutaneous Infantile Hemangiomas of the Lower Body and Regional Congenital Anomalies.
    15. Spence-Shishido A et al. Hemangiomas and the eye. Clinics in Dermatology (2015) 33, 170-182
    16. Schwartz S et al. Risk Factors for Amblyopia in Children with Capillary Hemangiomas of the Eyelids and Orbit. J AAPOS 2006;10:262-268

Authors:
Andrew McCormick, MD — Medical Director, Vascular Anomalies Center, UPMC Children’s Hospital of Pittsburgh Associate Professor of Pediatrics, University of Pittsburgh School of Medicine
No relationships with industry relevant to the content of this educational activity have been disclosed.
Tony R. Tarchichi MD — Assistant Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC) Paul C. Gaffney Diagnostic Referral Group
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.